Page 7 - CUA 2020_Onco_Bladder
P. 7

Unmoderated Posters 2: Uro-Oncology, Pediatrics, Sexual Dysfunction, Transplant






         UP-2.5. Table 1. Demographic and clinical factor comparison table for recurrent UTIs confirmed by 3 or more positive
         urine cultures in the previous year
                                                     Total             No               Yes             p
                                                     N=124            n=94              n=30

         Age, mean ± SD                             37.3±13.9        38.4±14.1        34.0±13.0        0.142
         Sex (%)
          Female                                   17 (13.7%)       10 (10.6%)        7 (23.3%)        0.123
          Male                                     107 (86.3%)      84 (89.4%)        23 (76.7%)
         BMI, mean ± SD                             25.7±6.3         25.3±6.1         26.7±6.8         0.336
         Race (%)
          Black                                    34 (27.4%)       21 (22.3%)        13 (43.3%)       0.033
          Other                                     12 (9.7%)        8 (8.5%)         4 (13.3%)
          White                                    78 (62.9%)       65 (69.1%)        13 (43.3%)
         SCI level of injury, n
          Cervical                                 42 (33.9%)       32 (34.0%)        10 (33.3%)       1.000
          Thoracic                                 72 (58.1%)       54 (57.4%)        18 (60.0%)
          Lumbar                                    10 (8.1%)        8 (8.5%)         2 (6.7%)
         Years since SCI, mean ± SD                 5.0±6.7           5.6±7.0          3.1±5.2         0.018
         History of diabetes mellitus (%)           6 (4.8%)         4 (4.3%)         2 (6.7%)         0.631
         History of decubitus ulcers (%)           26 (21.0%)       20 (21.3%)        6 (20.0%)        0.881
         Bladder stone(s) present (%)               8 (6.5%)         7 (7.4%)         1 (3.3%)         0.678
         Renal stone(s) present (%)                15 (12.1%)       13 (13.8%)        2 (6.7%)         0.358
         Hydronephrosis present (%)                 4 (3.2%)         2 (2.1%)         2 (6.7%)         0.246
         Vesicoureteral reflux present (%)          4 (3.2%)         4 (4.3%)         0 (0.0%)         0.571
         Reports urinary incontinence (%)          80 (64.5%)       59 (62.8%)        21 (70.0%)       0.471
         Anticholinergic medication use (%)        68 (54.8%)       51 (54.3%)        17 (56.7%)       0.837
         Antibiotic prophylaxis use (%)             9 (7.3%)         7 (7.4%)         2 (6.7%)         1.000
         DO present (%)                            88 (71.0%)       68 (72.3%)        20 (66.7%)       0.551
         Volume at first DO , median (range)      262.0 (38–850)   275.0 (38–850)   225.0 (56–550)     0.287
                       †
         Max Pdet during DO , median (range)       50.0 (9–180)     50.0 (9–180)     55.0 (25–149)     0.240
                        ‡
         Cystometric capacity, median (range)    475.0 (35–1346)   486.5 (73–1346)  395.0 (35–1225)    0.424
         End fill detrusor pressure, median (range)  7.5 (1–74)      7.5 (1–74)       7.5 (1–46)       0.699
         Compliance, median (range)              44.7 (1.1–475.0)  42.4 (4.5–475.0)  50.0 (1.1–375.0)  0.641
         Number of UTI in previous year*, mean ± SD  1.6±1.7          0.8±0.8          4.1±1.7         0.000
         † Volume at first DO corresponds to the infused volume during UDS at which the first uninhibited detrusor contraction occurred.  ‡ Max Pdet during DO corresponds to the maximum detrusor
         pressure obtained during an uninhibited detrusor contraction. This was run as a continuous variable. *Number of UTI in previous year corresponds to the number of culture-proven infec-
         tions within the previous year leading up to their presentation to urology.
        UP-2.6                                               Introduction: Surgical interventions continue to be the mainstay treatment
                  ®
        The Contino  urethral insert in the treatment of male stress   for men with stress urinary incontinence (SUI). For patients with comorbidi-
        urinary incontinence                                 ties that preclude them from surgery or those that are unwilling to undergo
                                 2
        Dean S. Elterman , Richard W. Casey , Thomas J. De los Reyes , Michael   invasive therapy, non-surgical options are limited to external compression or
                    1
                                                   1
        Holloway 3                                           collection devices coupled with behavioral modifications. These are often not
                                                                                            ®
                                                    2
        1 Urology, University Health Network, Toronto, ON, Canada;  The Fe/  satisfactory in controlling leakage. The Contino  is a self-administered device
                                        3
        Male Health Centres, Oakville, ON, Canada;  Life360 Innovations Inc.,   placed into the distal urethra to inhibit urine flow, which is then removed
        Vancouver, BC, Canada                                prior to urination. This prospective, non-randomized, single-arm trial was
                                                                                         ®
        Support: Life360 Innovations Inc. sponsored this study  used to assess the efficacy of the Contino  device in treating male SUI.
         UP-2.6. Table 1. ICIQ-SF data summaries by day
         Day                  n       Mean      SD       MIN      Median    MAX       Q1        Q3       IQR
         Baseline            26       16.5      3.7       9        17        21        14       19.8      5.8
         Interim             17       13.8      5.4       3        15        21        9        18        9
         End                 13       12.2      5.5       5        12        21        7        17        10
                                                CUAJ • June 2020 • Volume 14, Issue 6(Suppl2)                S59
   2   3   4   5   6   7   8   9   10   11   12